Stockwinners Market Radar for February 20, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:04 EST Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. The steep decline in Amazon's (AMZN) stock over the past year is roiling the technology company's stock-heavy compensation plan, resulting in employee pay coming in significantly lower than target compensation, The Wall Street Journal's Dana Mattioli and Sebastian Herrera report, citing people familiar with the matter. Amazon pays its corporate employees a large chunk of their annual salaries in restricted stock units, and a prolonged slump in the company's shares is causing pay for 2023 to be between 15% and 50% lower than the projected targets Amazon gave to employees, some of the people said. 2. Meta Platform's (META) Mark Zuckerberg announced that, "we'll begin testing a new offering called Meta Verified, a subscription bundle on Instagram and Facebook that includes a verified badge that authenticates your account with government ID, proactive account protection, access to account support, and increased visibility and reach. We're starting with a gradual test in Australia and New Zealand later this week to learn what's most valuable, and we hope to bring Meta Verified to the rest of the world soon.... Meta Verified is available for direct purchase on Instagram or Facebook in Australia and New Zealand starting later this week. People can purchase a monthly subscription for (USD) $11.99 on the web and (USD) $14.99 on iOS and Android." 3. Walmart (WMT) stock has barely budged over the past three months, but that looks about to change as it gets set to report earnings. The discount mega-retailer is benefiting from a shift in how the U.S. consumer is spending money, Al Root writes in this week's edition of Barron's. Walmart is trading at about 22 times estimated earnings over the coming 12 months, right in line with its historical average. That's a reasonable price to pay for Walmart at a moment when it finds itself in the retail sweet spot, the author argues. 4. Disney's (DIS) "Ant-Man and the Wasp: Quantomania" won the Presidents' Day long weekend with an estimated $118M debut, including 104M for the three days. Overseas, the Marvel movie earned $121.3M for a global start of $239.3M. Moviegoers gave the pic a B CinemaScore, while the Rotten Tomatoes' Tomatometer sits at only 48%. 5. Dow (DOW), LyondellBasell (LYB), Celanese (CE), Berry Global (BERY), Origin Materials (ORGN), Univar Solutions (UNVR), Waste Management (WM), Republic Services (RSG), and Waste Connections (WCN) saw positive mentions in this week's edition of Barron's.

17:46 EST Whirlpool declares quarterly dividend of $1.75 - The board of directors of Whirlpool declared a quarterly dividend of $1.75 per share on the company's common stock. The dividend is payable on March 15, 2023, to stockholders of record at the close of business on March 3, 2023.

17:43 EST Etsy tells The Fly 'counterfeit items, fraud explicitly prohibited' - An Etsy spokesperson told The Fly that, "Etsy is proud to be home to millions of unique, handcrafted, and customized goods, and the integrity of our marketplace is critical to our business. We are dedicated to fostering a trusted and safe platform, and as Etsy has grown, we have increased investments in a variety of sophisticated tools to protect our community against bad actors. Counterfeit items, fraud and other illicit practices are explicitly prohibited on Etsy, and our dedicated teams work diligently to remove listings that violate our policies." This comes after Citron Research published a critical report on Etsy, stating in part that, "management has knowingly or, at the very least, negligently, turned this company into the largest organized clearing house for counterfeit goods in the world while not only allowing the behavior but encouraging it and promoting it by selling placement and status to the millions of sites that regularly violate copyright laws."

16:59 EST Graphic Packaging declares quarterly dividend of 10c - Graphic Packaging announced that its Board of Directors declared a quarterly dividend of 10c per share of common stock to stockholders of record at the close of business on March 15, 2023. The dividend is payable on April 5, 2023.

15:17 EST PepsiCo recalling Starbucks vanilla Frappuccino bottles - PepsiCo (PEP) is recalling more than 25,000 cases of Starbucks (SBUX) vanilla Frappuccino beverages over concerns a foreign object - glass - might have gotten into some bottles, according to the Food and Drug Administration notice. Reference Link

14:44 EST Takeda Pharmaceutical presents results from Phase 3 GRAPHITE study - Takeda announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab achieved a statistically significant and clinically meaningful improvement in lower gastrointestinal aGvHD-free survival by Day 180 after allo-HSCT with no relevant differences in safety profile versus placebo. Intestinal aGvHD is a serious complication characterized by inflammation of the GI tract which can affect patients undergoing allo-HSCT, a common treatment for blood cancers. Vedolizumab is not currently indicated for use in aGvHD. The Phase 3, randomized, double-blind, placebo-controlled, multicenter GRAPHITE study evaluated the efficacy and safety of vedolizumab as prophylaxis for intestinal aGvHD in patients undergoing allo-HSCT from unrelated donors for the treatment of hematological malignancies. The study met its primary endpoint, with vedolizumab achieving a statistically significant improvement in intestinal aGvHD-free survival versus placebo by Day 180 after allo-HSCT. Statistically significant superiority of vedolizumab over placebo was also demonstrated for intestinal aGvHD-free and relapse-free survival by Day +180, and for Grade C-D aGvHD-free survival at Day +180. In addition, no relevant differences in safety profile between the vedolizumab and placebo arms were observed, and no new safety signals were identified. Treatment-related adverse events were reported in 24.8% versus 28.4%, and treatment related serious adverse events in 8.5% versus 6.5% of patients treated with placebo versus vedolizumab, respectively.

12:00 EST Cooper-Standard falls -14.3% - Cooper-Standard is down -14.3%, or -$2.53 to $15.15.

12:00 EST Cazoo rises 19.9% - Cazoo is up 19.9%, or 54c to $3.25.

12:00 EST U.S. Cellular rises 24.5% - U.S. Cellular is up 24.5%, or $5.15 to $26.15.

10:00 EST Cooper-Standard falls -14.3% - Cooper-Standard is down -14.3%, or -$2.53 to $15.15.

10:00 EST Cazoo rises 19.9% - Cazoo is up 19.9%, or 54c to $3.25.

10:00 EST U.S. Cellular rises 24.5% - U.S. Cellular is up 24.5%, or $5.15 to $26.15.

09:47 EST Cooper-Standard falls -14.3% - Cooper-Standard is down -14.3%, or -$2.53 to $15.15.

09:47 EST Cazoo rises 19.9% - Cazoo is up 19.9%, or 54c to $3.25.

09:47 EST U.S. Cellular rises 24.5% - U.S. Cellular is up 24.5%, or $5.15 to $26.15.